What are the most common ALK fusion partners in clinical practice, including those seen in non‑small‑cell lung cancer and ALK‑positive anaplastic large‑cell lymphoma?

ALK Fusion Partners

EML4 (echinoderm microtubule-associated protein-like 4) is the most common fusion partner with ALK in non-small cell lung cancer, accounting for the vast majority of cases and producing at least 13 different variants. 1, 2

Primary Fusion Partner in NSCLC

In non-small cell lung cancer, EML4-ALK represents the predominant fusion, occurring in approximately 2-7% of all NSCLC patients 1. This fusion is clinically significant because it defines a unique molecular subset that responds to ALK tyrosine kinase inhibitors, fundamentally altering treatment approach and prognosis.

Clinical Context

• Patients with ALK rearrangements typically present with:
  • Adenocarcinoma histology
  • Little to no smoking history
  • Younger age at diagnosis
  • More advanced stage disease 1

Alternative Fusion Partners

While EML4 dominates, multiple other fusion partners have been documented 1, 2:

In NSCLC:

The catalog has expanded dramatically with next-generation sequencing, identifying approximately 90 distinct fusion partners by 2020 3. Notable partners include:

• ATIC - reported in multiple cases
• TPM3 - documented fusion partner
• Novel partners: GCC2, LMO7, PHACTR1, ZFPM2, TRIM24 4, 5

Important clinical note: Many of these novel ALK fusion variants respond to approved ALK TKIs, making comprehensive molecular testing essential 3, 5.

In Anaplastic Large Cell Lymphoma (ALCL):

The fusion partner landscape differs significantly in ALCL:

• NPM1 (nucleophosmin) is the most common fusion partner in ALK-positive ALCL, occurring in approximately 40-60% of cases through the characteristic t(2;5) translocation 6, 7

• Variant (non-NPM1) fusion partners in ALCL include 8:

  • TPM3 (32% of variant cases) - associated with favorable prognosis, no relapses reported
  • ATIC (29% of variant cases) - potentially associated with higher relapse risk (5 of 8 patients relapsed)
  • Other rare partners

Clinical Implications by Fusion Type

Variant-Specific Considerations:

EML4-ALK variants matter clinically 4, 9:

• Short forms (variant 3): Associated with more advanced stage, frequent metastases, and potentially lower sensitivity to ALK inhibitors
• Long forms (variant 1): Better response to ALK inhibitors, more favorable outcomes
• Variant 2: Significantly lower risk of progression (median PFS not reached vs. 24 months; HR=0.35, P=0.02) 9

Testing Methodology:

The guidelines emphasize that FISH break-apart probe methodology and IHC (ALK D5F3 CDx Assay) are both acceptable for ALK detection 2. However, RNA-based NGS is essential for identifying rare fusion partners and specific variants, which may impact treatment selection and prognosis 3, 5.

Key Clinical Pitfalls

1. Don't rely on clinical enrichment alone: While ALK rearrangements are more common in never-smokers with adenocarcinoma, exceptions exist. Test broadly in advanced NSCLC 1.

2. Recognize mutual exclusivity: ALK rearrangements are typically mutually exclusive with EGFR and KRAS mutations, though rare exceptions occur 1.

3. Context matters: The fusion partner distribution differs dramatically between NSCLC (EML4-dominant) and ALCL (NPM1-dominant), requiring disease-specific interpretation 6, 7, 8.

4. Variant identification is prognostically relevant: When possible, identify the specific EML4-ALK variant, as this may influence treatment decisions and predict outcomes 4, 9.